01 11Perjeta
02 4Phesgo
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 3,628
2018 Revenue in Millions : 2,856
Growth (%) : 27
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 4,326
2019 Revenue in Millions : 3,924
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 4,256
2020 Revenue in Millions : 4,116
Growth (%) : 2
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 366
2020 Revenue in Millions : 24
Growth (%) : 1,378
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 809
2021 Revenue in Millions : 366
Growth (%) : 121
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 4,468
2021 Revenue in Millions : 4,256
Growth (%) : 5
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,299
2022 Revenue in Millions : 809
Growth (%) : 51
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 4,372
2022 Revenue in Millions : 4,468
Growth (%) : -8
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 3,983
2023 Revenue in Millions : 4,372
Growth (%) : -9
Pertuzumab/Trastuzumab/Hyaluronidase
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 1,917
2023 Revenue in Millions : 1,299
Growth (%) : 48
